Earnings call transcript: Bapcor faces challenges in H1 FY2026 By Investing.com

Bapcor reported a statutory NPAT loss of AUD 104.8m in H1 FY2026, driven by a AUD 110.3m post‑tax goodwill impairment in New Zealand; revenue fell 2.3% to AUD 973m and gross margin declined 5.5% (gross margin AUD 437.3m). Operating cash flow dropped to AUD 71.8m (down AUD 71.9m YoY) and capex fell to AUD 15.7m; management paused the interim dividend and announced a AUD 200m equity raising (AUD 0.60/share, ~65% discount) to repay debt and reduce pro forma net leverage to ~1.7x from 3.39x. Management is pursuing IT and supply‑chain investments, leadership restructuring, inventory rationalization (identifying ~AUD 100m excess stock) and targets underlying FY2026 EBITDA ~AUD 150–160m (post AASB16) and net leverage ≤2x, with expectations of improved trading over the next 6–12 months.

Analysis

The story is less about the headline loss and more about liquidity runway and operating leverage. Management has effectively bought time via a dilutive capital injection and lender concessions; that reduces near-term insolvency tail risk but transfers the primary risk to execution—turnaround outcomes now hinge on inventory rebalancing, pricing governance, and restoring branch-level competitiveness rather than additional financing events. Expect catalysts to be operational (weekly/monthly in‑stock and receivables trends) rather than big strategic M&A or macro moves.

Centralisation created a classic “last-mile” inefficiency: stock concentrated in fewer DCs increased freight and working capital friction while eroding local availability. The low‑hanging margin uplift is tactical—shift slow‑turn SKUs to central pick/ship, reallocate high‑turn/high‑margin items to stores, tighten discount controls—and could show through to gross‑margin and cash conversion within 3–9 months if executed crisply. Suppliers and third‑party logistics partners will feel negotiated pressure on lead times and pricing; expect accelerated tendering and potential short-term vendor concentration risk.

Competitors with cleaner inventories and disciplined pricing will be the immediate beneficiaries if execution slips—market share can move quickly in non‑discretionary aftermarket segments. Conversely, if management demonstrates sequential improvements in fill rates and a materially lower net leverage profile, the equity re‑rating could be sharp because much negative sentiment is already priced in. Key monitoring windows: the next two quarterly trading updates (monthly sales/in‑stock signals in between) and lender covenant testing points tied to leverage metrics.

Key Decisions for Investors

• Pair trade (3–6 months): Short Bapcor (BAP.AX) equity vs long SRG (SRG) — Entry after entitlement offer pricing finalised; target 30–40% gross upside on the short if operational progress lags, with a stop if BAP shows two consecutive months of meaningful in‑stock improvement and cash conversion. Rationale: dilution + execution risk vs competitor share capture.
• Credit play (12–24 months): Accumulate Bapcor senior paper or buy the bond with 1–3 year tenor on weakness — objective total return from deleveraging and covenant relief if turnaround executes. Risk: execution failure could widen spreads materially; position size to limit credit exposure to <1.5% NAV.
• Event‑driven equity entry (opportunistic): Go long Bapcor common only after (a) two consecutive months of like‑for‑like uplift in retail or trade sales and (b) demonstrable reduction in aged inventory/receivables. Timeframe: 3–9 months; target asymmetric upside because much negative information is priced in now, set a tight stop if either metric reverses.
• Monitoring action: Do not increase discretionary exposure until operational KPIs (weekly in‑stock, aged receivables, and month‑on‑month gross margin) trend positively for at least two consecutive reporting periods—these are the true inflection metrics that will separate a funded distressed name from a credible turnaround.